Covid-19

News

Lower COVID sales weigh on AZ in fourth quarter

Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.

R&D

JP Morgan 2023 – Alexandre LeVert

Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs

News

After COVID excess, Pfizer bracing for a hangover in 2023

Pfizer reaped the rewards of its COVID-19 vaccines and therapeutics in 2022, but there are already signs of falling demand that looks likely to get significantly worse in

News

FDA pulls AZ's Evusheld for COVID, citing lack of efficacy

AstraZeneca's revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against mo

News

US eyes link between Pfizer bivalent COVID jab and stroke

Regulatory authorities in the US are investigating a possible link between the new Pfizer/BioNTech bivalent COVID-19 booster vaccine and strokes in people aged 65 or over, but still recomme

News